Edgewise Therapeutics, Inc. (EWTX)
NASDAQ:EWTX
Want to see EWTX full AI Analyst Report?
EWTX Stock Chart & Stats
$34.43
-$0.39(-1.54%)
At close: 4:00 PM EST
$34.43
-$0.39(-1.54%)
Day’s Range― - ―
52-Week Range$12.15 - $40.77
Previous CloseN/A
Volume107.81K
Average Volume (3M)1.47M
Market Cap
$3.75B
Enterprise Value$3.65B
Total Cash (Recent Filing)$499.56M
Total Debt (Recent Filing)$3.79M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Aug 06, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding107,593,000
10 Day Avg. Volume1,850,212
30 Day Avg. Volume1,471,810
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.89
Price to Sales (P/S)0.00
P/FCF Ratio-17.76
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.18K
Enterprise Value/Ebitda-20.72
Forecast
1Y Price Target
$46.89Price Target Upside36.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeverageExtremely low debt relative to equity and sizable assets give the company durable funding flexibility to underwrite multi-year clinical programs. This reduces near-term insolvency risk, preserves strategic optionality for partnerships or organic development, and supports R&D continuity.
Large Upfront Proceeds From Asset SaleThe $1.55B upfront significantly boosts liquidity and is explicitly earmarked to fund EDG-7500 through potential approval and expand the cardiology portfolio. This structural capital infusion materially reduces near-term financing need and enables strategic refocus without immediate dilution.
Governance And Shareholder SupportStrong, recent shareholder backing of the board, auditor ratification and say-on-pay signal governance continuity and institutional confidence. Durable governance stability supports consistent strategy execution, regulatory interactions, and partner negotiations over the coming quarters.
Bears Say
Pre-Revenue StatusBeing pre-revenue is a fundamental risk: without product sales the company depends on external funding or asset transactions to support costly development. This leaves long-term viability tied to clinical outcomes and financing access rather than operational cash generation.
Sustained, Worsening Cash BurnSignificant and growing negative operating and free cash flow indicate the business cannot self-fund its R&D runway. Persistent burn increases reliance on large financing events or asset sales, constrains optionality for pipeline expansion, and raises execution risk over the medium term.
Narrowed Pipeline After Sevasemten SaleDivesting the lead neuromuscular asset materially narrows therapeutic diversification, concentrating long-term outcomes on the cardiology programs (EDG-7500, EDG-15400). This increases company-level binary risk: fewer independent shots on goal raise exposure to single-program failures.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics, Inc.’s price range in the past 12 months?
Edgewise Therapeutics, Inc. lowest stock price was $12.15 and its highest was $40.77 in the past 12 months.
What is Edgewise Therapeutics, Inc.’s market cap?
Edgewise Therapeutics, Inc.’s market cap is $3.75B.
When is Edgewise Therapeutics, Inc.’s upcoming earnings report date?
Edgewise Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 51 days.
How were Edgewise Therapeutics, Inc.’s earnings last quarter?
Edgewise Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.485 by $0.025.
Is Edgewise Therapeutics, Inc. overvalued?
According to Wall Street analysts Edgewise Therapeutics, Inc.’s price is currently Undervalued.
Does Edgewise Therapeutics, Inc. pay dividends?
Edgewise Therapeutics, Inc. does not currently pay dividends.
What is Edgewise Therapeutics, Inc.’s EPS estimate?
Edgewise Therapeutics, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Edgewise Therapeutics, Inc. have?
Edgewise Therapeutics, Inc. has 107,593,000 shares outstanding.
What happened to Edgewise Therapeutics, Inc.’s price movement after its last earnings report?
Edgewise Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.485. Following the earnings report the stock price went down -3.812%.
Which hedge fund is a major shareholder of Edgewise Therapeutics, Inc.?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.89 (36.19% Upside)
$46.89 (36.19% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 522.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $208.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.87%
12-Months-Change
Fundamentals
Return on Equity
-32.55%
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Company Description
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$46.89
▲(36.19% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
0.95% Insiders
12.71% Mutual Funds
72.96% Other Institutional Investors
4.36% Public Companies and
Individual Investors